

September 29, 2023

Fotona d.o.o.
Tina Bartolic
Quality Assurance and Regulatory Affairs
Stegne 7
Ljubljana, 1000, Slovenia

Re: K221274

Trade/Device Name: StarFormer, TightWave Regulation Number: 21 CFR 21CFR 890.5850 Regulation Name: Powered muscle stimulator

Regulatory Class: Class II Product Code: IPF, NGX Dated: April 12, 2022 Received: May 2, 2022

Dear Tina Bartolic:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

K221274 - Tina Bartolic Page 2

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jitendra V. Virani -S

CDR Jitendra Virani, MS, MBA
Assistant Director
DHT5B: Division of Neuromodulation
and Physical Medicine Devices
OHT5: Office of Neurological
and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2023 See PRA Statement below.

510(k) Number (if known)
K221274
Device Name
StarFormer
Indications for Use (Describe)
Fotona StarFormer is intended to be used under medical supervision for adjunctive therapy for the treatment of medical
diseases and conditions.
Fotona StarFormer is indicated for use in stimulating neuromuscular tissue for bulk muscle excitation in the legs or arms
for rehabilitative purposes.
-Relaxation of muscle spasm,
-Prevention or retardation of disuse atrophy,
-Increasing local blood circulation,
-Muscle re-education,
-Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis,
-Maintaining or increasing range of motion.
Fotona StarFormer is indicated for improvement of abdominal tone, for strengthening of the abdominal muscles, for
development of firmer abdomen
-Strengthening, Toning and Firming of buttocks and thighs
Type of Use (Select one or both, as applicable)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

Over-The-Counter Use (21 CFR 801 Subpart C)

Prescription Use (Part 21 CFR 801 Subpart D)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510k Summary

SUBMITTER'S INFORMATION

Submitter: Fotona d.o.o.

Stegne 7

1000 Ljubljana, Slovenia Phone: +386 1 5009 100 Fax: +386 1 5009 200

Contact Person: Tina Bartolic, Quality Assurance and Regulatory Affairs Specialist

Phone: + 386 1 5009 100

E-mail: tina.bartolic@fotona.com

Date: April 12, 2022

DEVICE INFORMATION

Device Trade Name: StarFormer

Common name: Magnetic Stimulator

Classification name: Stimulator, Muscle, Powered

21 CFR 890.5850, Class II

Product Code: IPF, NGX

PREDICATE DEVICES

- Neotonus MS-101 Magnetic Muscle Stimulator System (K973929)

- Johari Digital Healthcare Ltd., TORC BODY (K131291)

DEVICE DESCRIPTION SUMMARY

StarFormer is a non-invasive therapeutic device. The device comprises a magnetic stimulation coil located in the applicator which is placed over the treatment area. During the treatment, an alternating electric current is sent into the stimulation coil. The alternations in the electric current produce electromagnetic field that interacts with the tissues of the human body. The device consists of a system controller board which also drives the touchscreen and the GUI, a high voltage current power supply and an applicator with electromagnetic coil.

INDICATIONS FOR USE

Fotona StarFormer is intended to be used under medical supervision for adjunctive therapy for the treatment of medical diseases and conditions.

Fotona StarFormer is indicated for use in stimulating neuromuscular tissue for bulk muscle excitation in the legs or arms for rehabilitative purposes.

- -Relaxation of muscle spasm,
- -Prevention or retardation of disuse atrophy,
- -Increasing local blood circulation,
- -Muscle re-education,
- -Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis,
- -Maintaining or increasing range of motion.

Fotona StarFormer is indicated for

improvement of abdominal tone, for strengthening of the abdominal muscles, for development of firmer abdomen

-Strengthening, Toning and Firming of buttocks and thighs

INDICATIONS FOR USE COMPARISON

The indications for use are based on previously cleared indications for the substantially equivalent predicate devices, Neotonus MS-101 Magnetic Stimulator System (K973929) (primary predicate) and Johari Digital Healthcare Ltd., TORC BODY (K131291) (second predicate).

TECHNOLOGICAL COMPARISON

A technical specifications comparison of StarFormer with predicate devices, Neotonus MS-101 Magnetic Stimulator System (K973929) (primary predicate) and Johari Digital Healthcare Ltd., TORC BODY (K131291) (second predicate), is presented in the table below.

Manufacturer	Neotonus, Inc.	Johari Digital	Fotona d.o.o.	
		HealthCare Ltd.		
Device name	MS-101 Magnetic	TORC BODY	StarFormer	
	Muscle Stimulator			SE determination
	System			
	(Primary	(Cocond predicate)	(Subject device)	
	predicate)	(Second predicate)		
510 (k) number	K973929	K131291	K221274	~
Indications for	The Neotonus MS-101	TORC BODY is indicated to be used for:	Fotona StarFormer is intended to be used	Same
use	Magnetic Muscle Stimulator System is		under medical	
	intended to be used under	- Improvement of abdominal tone, for	supervision for	
	medical supervision for	strengthening of the	adjunctive therapy for	
	adjunctive therapy for the	abdominal muscles, for	the treatment of medical	
	treatment of medical	development of firmer	diseases and conditions.	
	diseases and conditions.	abdomen.	Fotona StarFormer is indicated for use in	
	The Neotonus MS-101 Magnetic Muscle	- Strengthening, Toning	stimulating	
	Stimulator System is	and Firming of buttocks	neuromuscular tissue for	
	indicated for use in	and thighs.	bulk muscle excitation in	
	stimulating neuromuscular		the legs or arms for	
	tissue for bulk muscle		rehabilitative purposes.	
	excitation in the legs or arms for rehabilitative		-Relaxation of muscle	
	purposes.		spasm, -Prevention or	
	Indications for Use for		retardation of disuse	
	Muscle Stimulators:		atrophy,	
	-Relaxation of muscle		-Increasing local blood	
	spasms		circulation,	
	-Prevention or		-Muscle re-education,	
	retardation of disuse		-Immediate post-surgical stimulation of calf	
	atrophy		muscles to prevent	
	-Increasing local blood		venous thrombosis,	
	circulation		-Maintaining or	
	-Muscle re-education		increasing range of	
	-Immediate post-surgical		motion.	
	stimulation of calf		Fotona StarFormer is	
	muscles to prevent		indicated for	
	venous thrombosis		improvement of	
	-Maintaining or		abdominal tone, for	
	increasing range of motion		strengthening of the	
			abdominal muscles, for	
			development of firmer abdomen	
			-Strengthening, Toning	
			and Firming of buttocks	
			and thighs	
•	Muscle stimulation	Muscle stimulation	Muscle stimulation	Same
Principle of	Initiating action potential	Initiating action	Initiating action potential	
action	of nerves that results in	potential of nerves that	of nerves that results in	
	muscle contraction.	results in muscle contraction.	muscle contraction.	
Type of energy	Magnetic field	Electrical	Magnetic field	Same as primary
Type of energy	Triagnotic nota	Licenteni		predicate, different
				to second predicate,
				but the difference
				does not raise

				T
				different questions on safety and effectiveness therefore not
				important for SE
				determination.
				Principal of action
				is the same.
Product code	Physical medicine	Physical medicine	Physical medicine	Same
regulation	21 CFR 890.5850 IPF-Stimulator, Muscle,	21 CFR 890.5850 NGX-Stimulator,	21 CFR 890.5850 IPF-Stimulator, Muscle,	
	Powered	Muscle, Powered, For	Powered	
		Muscle Conditioning	NGX-Stimulator, Muscle,	,
			Powered, For Muscle	
Dulsa vanatitian	1-55 Hz	1-200 Hz	Conditioning 1-80 Hz	No impost
Pulse repetition rate	1-33 ПZ	1-200 ПZ	1-80 ПZ	No impact.
1400				The pulse
				repetition rate of
				StarFormer it is not
				significantly different from the
				primary predicate.
				Pulse repetition
				rate of StarFormer is witih the range
				of the second
				predicate.
				The pulse
				repetition rates of StarFormer and
				predicate devices
				are in the typical
				clinical range of
				devices intended for muscle
				stimulation of up to
				200 Hz (from
	200/			510(k) database).
Pulse duration	$275~\mu s \pm 20\%$	290 μs	330 μs	No impact.
				StarFormer's pulse
				duration is within the range of the primary
				predicate ($\pm 20\%$).
				Ì
				StarFormer's pulse duration is not
				significantly different
				from the second
				predicate (within 10% range) and has no
				significant impact on
				safety and efficacy of
				the device/therapy. The pulse width of the
				StarFormer device and
				the predicate devices are in the typical
				clinical range
				of 50 to 500 µs.
				Reference: "The effect

				of stimulus
				current pulse width on
				nerve fiber size
				recruitment patterns"
				by Robert B.
				Szlavik and Hubert de
				Bruin.
Pulse shape	Symmetrical biphasic	Symmetrical biphasic	Symmetrical biphasic	Same
Magnetic field	Up to 2.2 T	NA	Up to 2.2 T	Same
intensity				
User interface	Graphical Display	Touch screen	Touch screen	Same
Number of	1	1	1	Same
Output Modes				
Number of	1	2	1	Similar, but not
Output Channels				significantly
				different. This
				information is not
				relevant for SE
				evaluation. The
				number of output
				channel is related
				to the device type.
Software/	Yes	Yes	Yes	Same
Firmware/				
Microprocessor				
Control		1		
Timer Ranger	Yes	Yes	Yes	Same
ON Time	1 s to 30 s	Not publicly available	1 s to 20 s	Clinical outcome is
(device`s duty				independent of
cycle)	0 + 60	NI 411' 1 '1 11	0 4 240	duty cycle.
OFF Time	0 s to 60 s	Not publicly available	0 s to 240 s	ON/OFF periods are more related to
(device`s duty				
cycle)				technological limitations, namely
				overheating of the
				coil (OFF period).
				Therefore, this
				comparison is not
				relevant for SE
				evaluation.
Therapy Time	30, 60 min	Up to 60 min	Up to 30 min	Similar.
		- F 10 00 55555	of the state of th	Since the treatment
				parameters are set
				individually and
				are based on a
				patient pain
				threshold, this
				comparison is not
				relevant for SE
				evaluation.
Weight	28 kg	/	50 kg	Similar. Not
=	=		-	relevant for SE
				evaluation since it
				does not affect
				safety and
				effectiveness.
Dimenison	500 x 580 x 230 mm	200 x 150 x 100 mm	421 x 843 x 630 mm	Similar. Not
$[\mathbf{W} \mathbf{x} \mathbf{H} \mathbf{x} \mathbf{D}]$				relevant for SE
,				evaluation since it
				does not affect
				safety and
	1	1	1	, J

				effectiveness.
Housing	Not publicly available	ABS body enclosure	Device body is made of	This information is
Materials and			steel and plastic.	not relevant for SE
Construction				evaluation since no
			Applicators are made of	part of the
			plastics.	(subject) device
				comes in the direct
				contact with the
				patient.

Technological differences between subject and predicate devices do not raise new type of safety and effectiveness questions and are therefore deemed substantial equivalent.

NON-CLINICAL AND/OR CLINICAL TESTS SUMMARY AND CONCLUSIONS

Non-Clinical Summary:

StarFormer has been evaluated via verification and validation tests for conformance to the applicable regulations and safety standards. StarFormer is designed, tested, and will be manufactured in accordance with following standards:

CB Scheme standards:

IEC 60601-1:2005 + A1:2012

Medical electrical equipment - Part 1: General requirements for basic safety and essential performance.

IEC 60601-1-2:2014

Medical electrical equipment – Part 1-2: General requirements for basic safety and essential performance – Collateral Standard: Electromagnetic disturbances – Requirements and tests.

IEC 60601-1-6:2010 + A1:2013

Medical electrical equipment - Part 1-6: General requirements for basic safety and essential performance - Collateral standard: Usability.

IEC 62366-1:2015

Medical devices - Application of usability engineering to medical devices.

IEC 62304:2006 + A1:2015

Medical device Software – software life-cycle process.

ISO standards:

ISO 14971:2019

Medical devices — Application of risk management to medical devices

Clinical Summary:

No premarket clinical investigations were conducted since the performance of StarFormer is based on the well-established magnetic stimulation technology and does not carry significant residual risk for patients.

Conclusions:

StarFormer's indications for use and technological characteristics do not raise new type of questions regarding safety and efficacy when compared to both predicates. Based on technical characteristics, design, functional features, performance, and indications for use as listed above, StarFormer is considered to be substantially equivalent to the selected predicate devices.